Celgene Corporation Company Profile (NASDAQ:CELG)

About Celgene Corporation (NASDAQ:CELG)

Celgene Corporation logoCelgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CELG
  • CUSIP: 15102010
  • Web: www.celgene.com
Capitalization:
  • Market Cap: $94.92 billion
  • Outstanding Shares: 782,350,000
Average Prices:
  • 50 Day Moving Avg: $141.30
  • 200 Day Moving Avg: $130.43
  • 52 Week Range: $96.93 - $147.17
P/E:
  • Trailing P/E Ratio: 37.58
  • Foreward P/E Ratio: 13.62
  • P/E Growth: 0.86
Sales & Book Value:
  • Annual Revenue: $12.19 billion
  • Price / Sales: 7.79
  • Book Value: $10.80 per share
  • Price / Book: 11.23
Profitability:
  • EBITDA: $4.83 billion
  • Net Margins: 21.35%
  • Return on Equity: 68.51%
  • Return on Assets: 17.04%
Debt:
  • Debt-to-Equity Ratio: 1.63%
  • Current Ratio: 4.05%
  • Quick Ratio: 3.89%
Misc:
  • Average Volume: 3.71 million shs.
  • Beta: 1.88
  • Short Ratio: 2.63
 

Frequently Asked Questions for Celgene Corporation (NASDAQ:CELG)

What is Celgene Corporation's stock symbol?

Celgene Corporation trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene Corporation's stock split? How did Celgene Corporation's stock split work?

Shares of Celgene Corporation split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were issued to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene Corporation stock prior to the split would have 200 shares after the split.

How were Celgene Corporation's earnings last quarter?

Celgene Corporation (NASDAQ:CELG) posted its quarterly earnings data on Thursday, July, 27th. The company reported $1.82 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to analysts' expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business's revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.44 EPS. View Celgene Corporation's Earnings History.

When will Celgene Corporation make its next earnings announcement?

Celgene Corporation is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Celgene Corporation.

What guidance has Celgene Corporation issued on next quarter's earnings?

Celgene Corporation updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $7.25-7.35 for the period, compared to the Thomson Reuters consensus estimate of $7.29. The company issued revenue guidance of $13.0-13.4 billion, compared to the consensus revenue estimate of $13.19 billion.

Where is Celgene Corporation's stock going? Where will Celgene Corporation's stock price be in 2017?

27 analysts have issued 1-year price objectives for Celgene Corporation's stock. Their predictions range from $98.00 to $175.00. On average, they anticipate Celgene Corporation's share price to reach $150.77 in the next year. View Analyst Ratings for Celgene Corporation.

What are analysts saying about Celgene Corporation stock?

Here are some recent quotes from research analysts about Celgene Corporation stock:

  • 1. According to Zacks Investment Research, "Celgene’s Revlimid continued to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – also performed well. The consecutive increase in annual earnings guidance is also a positive. Celgene continues to progress with its label expansion efforts and pipeline development with sNDA submission for Revlimid in newly diagnosed multiple myeloma targeted for first-quarter 2018. The approval of Idhifa in the U.S. for relapsed and/or refractory acute myeloid leukemia has further boosted the company’s portfolio. Moreover, shares of Celgene have outperformed the industry in the year so far. However, Celgene is highly dependent on Revlimid while foreign exchange headwinds are expected to continue while Abraxane sales are under competitive pressure." (10/18/2017)
  • 2. Cann analysts commented, "Celgene announced that Idhifa (enasidenib/AG-221) was granted approval from FDA for the treatment of adult patients with relapsed or refractory AML with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test. It was reported that FDA approval was based on the clinical data from an open-label, single-arm, multicenter, two-cohort clinical trial of adult patients with relapsed or refractory AML with an IDH2 mutation (Study AG221-C-001, NCT01915498). Idhifa was approved concurrently with the Abbott RealTime IDH2 companion diagnostic test, which is FDA-approved as an aid in identifying AML patients for treatment with Idhifa." (8/1/2017)
  • 3. Cantor Fitzgerald analysts commented, "Acquisition of worldwide Rights to BeiGene,s (NASDAQ: BGNE, NC) excluding Asia, PD-1 inhibitor for solid tumors, BGB-A317, enhances CELG’s oncology portfolio and augments its immuno-oncology efforts." (7/6/2017)

Who are some of Celgene Corporation's key competitors?

Who are Celgene Corporation's key executives?

Celgene Corporation's management team includes the folowing people:

  • Robert J. Hugin, Executive Chairman of the Board
  • Scott A. Smith, President, Chief Operating Officer
  • Mark J. Alles, Chief Executive Officer, Director
  • Peter N. Kellogg, Chief Financial Officer, Executive Vice President
  • Terrie Curran, President, Global Inflammation & Immunology Franchise
  • Michael F. Pehl, President, Hematology & Oncology
  • Rupert J. Vessey, President - Research and Early Development
  • Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary
  • Michael D. Casey, Lead Independent Director
  • Michael W. Bonney, Director

Who owns Celgene Corporation stock?

Celgene Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Robeco Institutional Asset Management B.V. (0.09%), Fisher Asset Management LLC (0.03%), Inverness Counsel LLC NY (0.03%), Shell Asset Management Co. (0.02%), Bridges Investment Management Inc. (0.02%) and Mutual of America Capital Management LLC (0.02%). Company insiders that own Celgene Corporation stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene Corporation.

Who sold Celgene Corporation stock? Who is selling Celgene Corporation stock?

Celgene Corporation's stock was sold by a variety of institutional investors in the last quarter, including Bridges Investment Counsel Inc., Robeco Institutional Asset Management B.V., Private Asset Management Inc., Inverness Counsel LLC NY, Summit X LLC, Sumitomo Life Insurance Co., Indiana Trust & Investment Management CO and Sit Investment Associates Inc.. Company insiders that have sold Celgene Corporation stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Insider Buying and Selling for Celgene Corporation.

Who bought Celgene Corporation stock? Who is buying Celgene Corporation stock?

Celgene Corporation's stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Shell Asset Management Co., Centre Asset Management LLC, Rockefeller Financial Services Inc., Mutual of America Capital Management LLC, Meeder Asset Management Inc., Eqis Capital Management Inc. and Howe & Rusling Inc.. Company insiders that have bought Celgene Corporation stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene Corporation.

How do I buy Celgene Corporation stock?

Shares of Celgene Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene Corporation's stock price today?

One share of Celgene Corporation stock can currently be purchased for approximately $121.33.


MarketBeat Community Rating for Celgene Corporation (NASDAQ CELG)
Community Ranking:  4.0 out of 5 (star star star star)
Outperform Votes:  1,596 (Vote Outperform)
Underperform Votes:  422 (Vote Underperform)
Total Votes:  2,018
MarketBeat's community ratings are surveys of what our community members think about Celgene Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Celgene Corporation (NASDAQ:CELG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 5 Hold Ratings, 20 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $150.77 (24.26% upside)
Consensus Price Target History for Celgene Corporation (NASDAQ:CELG)
Price Target History for Celgene Corporation (NASDAQ:CELG)
Analysts' Ratings History for Celgene Corporation (NASDAQ:CELG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/20/2017Leerink SwannReiterated RatingBuy$156.00N/AView Rating Details
10/20/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$170.00N/AView Rating Details
10/20/2017Wells Fargo & CoReiterated RatingBuy$163.00N/AView Rating Details
10/20/2017Barclays PLCLower Price TargetEqual Weight$140.00 -> $135.00N/AView Rating Details
10/20/2017William BlairReiterated RatingOutperformN/AView Rating Details
10/20/2017Stifel NicolausLower Price TargetBuy$155.00 -> $149.00N/AView Rating Details
10/20/2017Citigroup Inc.DowngradeBuy -> NeutralN/AView Rating Details
10/20/2017Robert W. BairdDowngradeOutperform -> Neutral$162.00 -> $136.00N/AView Rating Details
10/16/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
10/17/2017Sanford C. BernsteinInitiated CoverageOutperform$162.00N/AView Rating Details
10/17/2017BMO Capital MarketsBoost Price TargetPositive$160.00 -> $167.00N/AView Rating Details
10/16/2017Jefferies Group LLCReiterated RatingBuy$160.00N/AView Rating Details
10/16/2017Cantor FitzgeraldSet Price TargetBuy$162.00N/AView Rating Details
10/5/2017Royal Bank Of CanadaReiterated RatingBuy$173.00N/AView Rating Details
10/5/2017Morgan StanleyDowngradeEqual Weight -> Underweight$120.00N/AView Rating Details
9/15/2017MizuhoBoost Price TargetBuy -> Buy$134.00 -> $158.00MediumView Rating Details
9/13/2017Bank of America CorporationReiterated RatingBuyLowView Rating Details
9/12/2017Cowen and CompanyReiterated RatingBuy$150.00LowView Rating Details
9/5/2017BTIG ResearchReiterated RatingNeutralLowView Rating Details
8/1/2017CannReiterated RatingBuy$175.00LowView Rating Details
7/31/2017ArgusUpgradeHold -> Buy$96.93 -> $160.00LowView Rating Details
7/27/2017Canaccord GenuitySet Price TargetBuy$156.00LowView Rating Details
7/14/2017SunTrust Banks, Inc.Reiterated RatingBuy$150.00LowView Rating Details
7/6/2017Credit Suisse GroupSet Price TargetBuy$148.00LowView Rating Details
5/17/2017Goldman Sachs Group, Inc. (The)Reiterated RatingSell$93.00 -> $98.00LowView Rating Details
1/8/2017Evercore ISIReiterated RatingBuy$135.00N/AView Rating Details
11/9/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
10/18/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
7/6/2016JMP SecuritiesReiterated RatingBuy$152.00N/AView Rating Details
4/28/2016Raymond James Financial, Inc.Reiterated RatingBuyN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral -> NeutralN/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Celgene Corporation (NASDAQ:CELG)
Earnings by Quarter for Celgene Corporation (NASDAQ:CELG)
Earnings History by Quarter for Celgene Corporation (NASDAQ CELG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017$1.89N/AView Earnings Details
7/27/20176/30/2017$1.61$1.82$3.23 billion$3.27 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.47$1.68$3.04 billion$2.96 billionViewN/AView Earnings Details
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.31$1.58$2.84 billion$2.98 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.09$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$0.93$0.95$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.88$0.91$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.82$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.77$0.80$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celgene Corporation (NASDAQ:CELG)
2017 EPS Consensus Estimate: $6.61
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.44$1.46$1.45
Q2 20173$1.61$1.68$1.64
Q3 20173$1.68$1.81$1.73
Q4 20173$1.72$1.84$1.78
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celgene Corporation (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celgene Corporation (NASDAQ:CELG)
Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 79.24%
Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)
Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)
Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/25/2017Terrie CurranInsiderSell1,727$143.89$248,498.03View SEC Filing  
9/12/2017Gilla KaplanDirectorSell9,250$141.56$1,309,430.00View SEC Filing  
9/5/2017Michael D CaseyDirectorSell9,250$139.03$1,286,027.50View SEC Filing  
8/10/2017Ernest MarioDirectorSell18,506$130.52$2,415,403.12View SEC Filing  
8/2/2017Gilla KaplanDirectorSell7,500$134.52$1,008,900.00View SEC Filing  
6/26/2017James J LoughlinDirectorSell18,500$133.57$2,471,045.00View SEC Filing  
6/22/2017Michael A FriedmanDirectorSell10,000$132.50$1,325,000.00View SEC Filing  
6/22/2017Robert J HuginInsiderSell175,970$134.14$23,604,615.80View SEC Filing  
6/21/2017Michael D CaseyDirectorSell9,250$133.05$1,230,712.50View SEC Filing  
6/19/2017Michael D. CaseyDirectorSell9,250$125.59$1,161,707.50View SEC Filing  
6/15/2017Rupert VesseyInsiderSell4,785$120.18$575,061.30View SEC Filing  
5/1/2017James J LoughlinDirectorSell9,250$124.00$1,147,000.00View SEC Filing  
3/30/2017Gilla KaplanDirectorSell14,033$123.83$1,737,706.39View SEC Filing  
3/1/2017Rupert VesseyInsiderSell4,000$124.42$497,680.00View SEC Filing  
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.00View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.56View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.00View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.40View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.00View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.00View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.00View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.28View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.00View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.00View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.68View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.00View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.16View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.78View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.00View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.78View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Celgene Corporation (NASDAQ:CELG)
Latest Headlines for Celgene Corporation (NASDAQ:CELG)
Source:
DateHeadline
finance.yahoo.com logoCelgene Abandons Crohn's Drug; Could Others Take Its Spot?
finance.yahoo.com - October 20 at 8:27 PM
finance.yahoo.com logoHere are 4 home run stocks to kick off the World Series: ...
finance.yahoo.com - October 20 at 8:27 PM
finance.yahoo.com logoCelgene Down on Discontinued Crohn's Disease Drug Study
finance.yahoo.com - October 20 at 8:27 PM
finance.yahoo.com logoCelgene Stock: Performance in 3Q17
finance.yahoo.com - October 20 at 8:27 PM
americanbankingnews.com logoCelgene Corporation (CELG) Earns "Buy" Rating from Wells Fargo & Co
www.americanbankingnews.com - October 20 at 7:40 PM
americanbankingnews.com logoCelgene Corporation's (CELG) "Buy" Rating Reiterated at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 20 at 7:40 PM
americanbankingnews.com logoCelgene Corporation (CELG) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - October 20 at 7:04 PM
fool.com logoHow Big of a Deal Is Celgene's Flop?
www.fool.com - October 20 at 4:09 PM
forbes.com logoCelgene is Now Oversold - Forbes
www.forbes.com - October 20 at 3:25 PM
investorplace.com logoCatch This Falling Knife — Go Long Celgene Corporation - Investorplace.com
investorplace.com - October 20 at 3:25 PM
fool.com logoWhy Celgene Corporation Dropped Today - Motley Fool
www.fool.com - October 20 at 3:25 PM
finance.yahoo.com logoGLOBAL MARKETS-U.S. tax plan hopes lift stocks, strengthen dollar
finance.yahoo.com - October 20 at 3:25 PM
finance.yahoo.com logoBiotech Earnings: Good News on the Way
finance.yahoo.com - October 20 at 3:24 PM
finance.yahoo.com logoCelgene dives 10% after ditching key drug
finance.yahoo.com - October 20 at 3:24 PM
finance.yahoo.com logoHow Big of a Deal Is Celgene's Flop?
finance.yahoo.com - October 20 at 3:24 PM
finance.yahoo.com logoTax Progress Boosts Wall Street, Major Indexes Trade Above Records
finance.yahoo.com - October 20 at 3:24 PM
fool.com logoWhy Celgene Corporation Dropped Today
www.fool.com - October 20 at 2:55 PM
seekingalpha.com logoCelgene selloff weighs on biotechs, IBB down 1%
seekingalpha.com - October 20 at 1:46 PM
feeds.benzinga.com logoCelgene's Pipeline In Question After GED Failure
feeds.benzinga.com - October 20 at 11:59 AM
americanbankingnews.com logoCelgene Corporation (CELG) Given "Outperform" Rating at William Blair
www.americanbankingnews.com - October 20 at 11:42 AM
investorplace.com logoCatch This Falling Knife — Go Long Celgene Corporation
investorplace.com - October 20 at 10:47 AM
seekingalpha.com logoCelgene to record pre-tax charge as high as $500M in Q4 for mongersen stop; shares down 5% premarket
seekingalpha.com - October 20 at 7:45 AM
marketwatch.com logoCelgene shares drop after Crohn's disease drug trials halted - MarketWatch
www.marketwatch.com - October 20 at 3:39 AM
reuters.com logoCelgene abandons Crohn's disease drug trials - Reuters
www.reuters.com - October 19 at 10:38 PM
businesswire.com logoCelgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program - Business Wire (press release)
www.businesswire.com - October 19 at 10:37 PM
streetinsider.com logoCelgene (CELG) to Stop GED-0301 Phase III REVOLVE Trial Following Interim Futility Analysis
www.streetinsider.com - October 19 at 5:37 PM
reuters.com logoBRIEF-Celgene provides update on GED-0301 (mongersen) inflammatory bowel disease program
www.reuters.com - October 19 at 5:37 PM
finance.yahoo.com logoPhase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting
finance.yahoo.com - October 19 at 5:37 PM
finance.yahoo.com logoCelgene: Look Beyond Any Short-Term Weakness
finance.yahoo.com - October 19 at 5:37 PM
finance.yahoo.com logoCelgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
finance.yahoo.com - October 19 at 5:37 PM
finance.yahoo.com logoCelgene discontinues trial of Crohn's disease drug
finance.yahoo.com - October 19 at 5:37 PM
finance.yahoo.com logoCelgene abandons Crohn's disease drug trials
finance.yahoo.com - October 19 at 5:37 PM
finance.yahoo.com logoCelgene reopens, shares plunge
finance.yahoo.com - October 19 at 5:37 PM
finance.yahoo.com logoCelgene shares drop after Crohn's disease drug trials halted
finance.yahoo.com - October 19 at 5:37 PM
finance.yahoo.com logoCelgene Falls After Scrapping Crohn's Disease Drug Trials
finance.yahoo.com - October 19 at 5:37 PM
cnbc.com logoCelgene won't initiate phase 3 trial for Crohn's disease drug
www.cnbc.com - October 19 at 5:20 PM
americanbankingnews.com logoCelgene Corporation (CELG) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - October 19 at 1:44 AM
americanbankingnews.com logoZacks Investment Research Lowers Celgene Corporation (CELG) to Hold
www.americanbankingnews.com - October 18 at 10:20 PM
bizjournals.com logoBreakfast Technical Briefing on Biotech Stocks -- BioCryst Pharma, Celgene, Juno Therapeutics, and Lexicon Pharma
www.bizjournals.com - October 18 at 6:23 PM
finance.yahoo.com logoTop Stock Reports for IBM, Celgene and Procter & Gamble
finance.yahoo.com - October 18 at 6:23 PM
americanbankingnews.com logoFY2017 EPS Estimates for Celgene Corporation Decreased by Analyst (CELG)
www.americanbankingnews.com - October 18 at 9:56 AM
americanbankingnews.com logoZacks: Analysts Expect Celgene Corporation (CELG) to Post $1.88 EPS
www.americanbankingnews.com - October 18 at 12:12 AM
nasdaq.com logoNotable ETF Outflow Detected - XLV, JNJ, PFE, CELG
www.nasdaq.com - October 17 at 5:51 PM
finance.yahoo.com logoTop 3 Healthcare Stocks for 2017
finance.yahoo.com - October 17 at 5:51 PM
americanbankingnews.com logoCelgene Corporation (CELG) PT Raised to $167.00
www.americanbankingnews.com - October 17 at 8:30 AM
americanbankingnews.com logoLeerink Swann Weighs in on Celgene Corporation's Q3 2017 Earnings (CELG)
www.americanbankingnews.com - October 17 at 7:34 AM
investorplace.com logoCelgene’s (CELG) Upgraded to Buy
investorplace.com - October 16 at 5:50 PM
finance.yahoo.com logoCelgene Blood Cancer Treatment: Just The Tip Of Its Disruptive Science?
finance.yahoo.com - October 16 at 5:50 PM
finance.yahoo.com logoResults from Phase 2 Studies of Oral Ozanimod in Crohn’s Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG2017
finance.yahoo.com - October 16 at 5:50 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Celgene Corporation and Valeant Pharmaceuticals
finance.yahoo.com - October 16 at 5:50 PM

Social

Chart

Celgene Corporation (CELG) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.